Literature DB >> 12200619

Hyperphosphorylated tau deposition parallels prion protein burden in a case of Gerstmann-Sträussler-Scheinker syndrome P102L mutation complicated with dementia.

Keisuke Ishizawa1, Takashi Komori, Tomokazu Shimazu, Toshimasa Yamamoto, Tetsuyuki Kitamoto, Kunio Shimazu, Takanori Hirose.   

Abstract

Hyperphosphorylated tau (p-tau) deposition has been documented in a limited population of patients with Gerstmann-Sträussler-Scheinker syndrome (GSS) with particular point mutations of the prion protein (PrP) gene. Although its pathogenesis is only poorly understood, p-tau in GSS is known to be identical to that in Alzheimer's disease (AD). We conducted immunohistochemical and quantitative image studies on the brain from a 44-year-old man with a 7-year history of dementia, diagnosed as having GSS with a point mutation of the PrP gene at codon 102 (GSS102), the commonest mutation in GSS. Severe spongiform degeneration and numerous PrP plaques were disclosed in the cerebral cortices and hippocampus, consistent with the diagnosis. However, rarely described in GSS102, prominent p-tau deposits as pretangles, neurofibrillary tangles and degenerating neurites were demonstrated adjacent to or around PrP plaques. beta-Amyloid protein (Abeta) plaques were generally sparse and appeared invariably to be of a diffuse type. Double-labeling immunohistochemistry yielded co-localization of p-tau with PrP but not with Abeta. Most PrP plaques did not contain Abeta. These results excluded a diagnosis of concomitant AD. Quantitative analysis on a fractional area density of immunoreactive pixels demonstrated that burdens of PrP and p-tau but not Abeta were significantly correlated. These results suggest that p-tau deposition in this GSS102 is secondarily induced by PrP but not by Abeta (secondary tauopathy). Our study also suggests that p-tau deposition might be a more common phenomenon in long-standing GSS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12200619     DOI: 10.1007/s00401-002-0547-3

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  17 in total

1.  Role of cyclin-dependent kinase 5 in the neurodegenerative process triggered by amyloid-Beta and prion peptides: implications for Alzheimer's disease and prion-related encephalopathies.

Authors:  Joao P Lopes; Catarina R Oliveira; Paula Agostinho
Journal:  Cell Mol Neurobiol       Date:  2007-10-27       Impact factor: 5.046

2.  Squirrel monkeys (Saimiri sciureus) infected with the agent of bovine spongiform encephalopathy develop tau pathology.

Authors:  P Piccardo; J Cervenak; O Yakovleva; L Gregori; K Pomeroy; A Cook; F S Muhammad; T Seuberlich; L Cervenakova; D M Asher
Journal:  J Comp Pathol       Date:  2011-10-20       Impact factor: 1.311

3.  Context dependent neuroprotective properties of prion protein (PrP).

Authors:  Andrew D Steele; Zhipeng Zhou; Walker S Jackson; Chunni Zhu; Pavan Auluck; Michael A Moskowitz; Marie-Francoise Chesselet; Susan Lindquist
Journal:  Prion       Date:  2009-10-16       Impact factor: 3.931

4.  Changes of tau profiles in brains of the hamsters infected with scrapie strains 263 K or 139 A possibly associated with the alteration of phosphate kinases.

Authors:  Gui-Rong Wang; Song Shi; Chen Gao; Bao-Yun Zhang; Chan Tian; Chen-Fang Dong; Rui-Min Zhou; Xiao-Li Li; Cao Chen; Jun Han; Xiao-Ping Dong
Journal:  BMC Infect Dis       Date:  2010-04-01       Impact factor: 3.090

5.  Human tau protein forms complex with PrP and some GSS- and fCJD-related PrP mutants possess stronger binding activities with tau in vitro.

Authors:  Xiao-Fan Wang; Chen-Fang Dong; Jin Zhang; Yan-Zhen Wan; Feng Li; Yin-Xia Huang; Lu Han; Bing Shan; Chen Gao; Jun Han; Xiao-Ping Dong
Journal:  Mol Cell Biochem       Date:  2007-11-25       Impact factor: 3.396

6.  Atypical frontotemporal dementia as a new clinical phenotype of Gerstmann-Straussler-Scheinker disease with the PrP-P102L mutation. Description of a previously unreported Italian family.

Authors:  Anna Rita Giovagnoli; Giuseppe Di Fede; Anna Aresi; Fabiola Reati; Giacomina Rossi; Fabrizio Tagliavini
Journal:  Neurol Sci       Date:  2008-11-21       Impact factor: 3.307

Review 7.  Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis.

Authors:  Phuong H Nguyen; Ayyalusamy Ramamoorthy; Bikash R Sahoo; Jie Zheng; Peter Faller; John E Straub; Laura Dominguez; Joan-Emma Shea; Nikolay V Dokholyan; Alfonso De Simone; Buyong Ma; Ruth Nussinov; Saeed Najafi; Son Tung Ngo; Antoine Loquet; Mara Chiricotto; Pritam Ganguly; James McCarty; Mai Suan Li; Carol Hall; Yiming Wang; Yifat Miller; Simone Melchionna; Birgit Habenstein; Stepan Timr; Jiaxing Chen; Brianna Hnath; Birgit Strodel; Rakez Kayed; Sylvain Lesné; Guanghong Wei; Fabio Sterpone; Andrew J Doig; Philippe Derreumaux
Journal:  Chem Rev       Date:  2021-02-05       Impact factor: 60.622

Review 8.  Tau, prions and Aβ: the triad of neurodegeneration.

Authors:  Lilla Reiniger; Ana Lukic; Jacqueline Linehan; Peter Rudge; John Collinge; Simon Mead; Sebastian Brandner
Journal:  Acta Neuropathol       Date:  2010-05-16       Impact factor: 17.088

9.  Activation of the unfolded protein response and granulovacuolar degeneration are not common features of human prion pathology.

Authors:  Vera I Wiersma; Wim van Hecke; Wiep Scheper; Martijn A J van Osch; Will J M Hermsen; Annemieke J M Rozemuller; Jeroen J M Hoozemans
Journal:  Acta Neuropathol Commun       Date:  2016-10-28       Impact factor: 7.801

10.  T-Tau and P-Tau in Brain and Blood from Natural and Experimental Prion Diseases.

Authors:  Richard Rubenstein; Binggong Chang; Robert Petersen; Allen Chiu; Peter Davies
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.